Prediction Model of Parotid Mean Dose in Intensity Modulated Radiation Therapy on Nasopharyngeal Carcinoma
-
摘要:目的
探讨鼻咽癌调强放疗时腮腺平均吸收剂量（Dmean）及其D50%的预测模型。
方法随机选取西南医科大学附属医院肿瘤科50例鼻咽癌调强放疗患者，采集初始放疗计划CT图像，分析腮腺体积与其Dmean和D50%之间的相关数学模型，在制作放疗计划前对腮腺的Dmean及其D50%进行预测。
结果鼻咽癌患者Voverlap/Vparotid与Dmean/Dprescription之间存在显著正相关性（置信度为0.01, r=0.895），Voverlap/Vparotid与D50%/Dprescription之间存在显著正相关性（置信度为0.01, r=0.812），并利用Matlab软件拟合出上述两者之间的相关公式。
结论鼻咽癌患者在制作放疗计划前可根据本研究所拟合出的相关数学模型，在给定处方条件下通过Voverlap/Vparotid，提前预测出Dmean与D50%，作为调强计划评估标准，从而减少放疗计划优化过程中主观因素造成的影响。
Abstract:ObjectiveTo investigate the prediction model of parotid mean dose and D50% in intensity modulated radiation therapy (IMRT) on nasopharyngeal carcinoma (NPC).
MethodsWe selected 50 NPC patients who underwent IMRT, scanned the radiotherapy plan CT, analyzed the relationship between the parotid volume and its mean absorbed dose and D50%, and predicted parotid mean dose and D50% before planning IMRT.
ResultsThere were significant correlation between Vparotid/Vparotid and Dmean/Dprescription (confidence coefficient=0.01, r=0.895), Voverlap/Vparotid and D50%/Dprescription (confidence coefficient=0.01, r=0.812). Matlab software was used to fit the correlation formula.
ConclusionFor the patients who underwent IMRT, we can predict Dmean and D50% by Voverlap/Vparotid under the prescription according to the relevant mathematical model fitted in this study before making the radiotherapy plan, and reduce the impact of subjective factors in the radiotherapy plan optimization process, as a standard for assessing programs.
-
-
![]()
图 2 Vparotid与Dmean/Dprescription之间散点图
Figure 2 Scatter plot between Vparotid and Dmean/Dprescription
![]()
图 3 Vparotid与D50%/Dprescription之间散点图
Figure 3 Scatter plot between Vparotid and D50%Dprescription
![]()
图 4 Voverlap/Vparotid与Dmean/Dprescription之间散点图
Figure 4 Scatter plot between Voverlap/Vparotid and Dmean/Dprescription
-
[1] Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2): 356-64. doi: 10.1016/j.ijrobp.2007.12.054
[2] Lin SJ, Pan JJ, Lu H, et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series[J]. Int J Radiat Oncol Biol Phys, 2009, 75(4): 1071-8. doi: 10.1016/j.ijrobp.2008.12.015
[3] Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2010, 76(1): 138-45. doi: 10.1016/j.ijrobp.2009.01.084
[4] Lee AW, Lau KY, Hung WM, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma[J]. Radiother Oncol, 2008, 87(2): 204-10. doi: 10.1016/j.radonc.2008.02.003
[5] Lai S, Li WF, Chen L, et al. How Does Intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiation Oncol Biol Phys, 2011, 80(3): 661-8. doi: 10.1016/j.ijrobp.2010.03.024
[6] Kam MK, Teo PM, Chan RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2004, 60(5): 1440-50. doi: 10.1016/j.ijrobp.2004.05.022
[7] Lin SJ, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: Experience of 370 consecutive cases[J]. BMC Cancer, 2010, 10: 39. doi: 10.1186/1471-2407-10-39
[8] Hunt MA, Jackson A, Narayana A, et al. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT[J]. Int J Radiat Oncol Biol Phys, 2006, 66(1): 296-304. doi: 10.1016/j.ijrobp.2006.05.028
[9] Kevin LM, Brame RS, Daniel A, et al. Experience-base quality control of clinical intensity-modulated radiotherapy planning[J]. Int J Radiat Oncol Biol Phys, 2011, 81(2): 545-51. doi: 10.1016/j.ijrobp.2010.11.030
[10] Lian J, Yuan L, Ge Y, et al. Modeling the dosimetry of organ-at-risk in head and neck IMRT planning: an intertechnique and interinstitutional study[J]. Med Phys, 2013, 40(12): 121704. doi: 10.1118/1.4828788
[11] 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志, 2010, 20(4): 267-9. http://cdmd.cnki.com.cn/Article/CDMD-10003-1015007282.htm Working committee for the clinical stage nasopharyngeal carcinoma (NPC) in China. 2010 expert consensus of nasopharyngeal carcinoma IMRT target and dosage design[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2010, 20(4): 267-9. http://cdmd.cnki.com.cn/Article/CDMD-10003-1015007282.htm
[12] Radiation Therapy Oncology Group. A phase Ⅱ study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) +Bevacizumab (BV) for locally or regionally advanced nasopharyngeal cancer (RTOG 0615)[R/OL].[2011-03-05].https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.IDRTOG0615.html.
[13] Radiation Therapy Oncology Group. A phase Ⅱ study of intensity modulated radiation therapy (IMRT) +/-chemotherapy for nasopharyngeal cancer (RTOG 0225) [R/OL]. [2011-03-05].https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.IDRTOG-0225. html.
[14] Zhu XF, Ge YR, Li TR, et al. A planning quality evaluation tool for prostate adaptive IMRT based on machine learning[J]. Med Phys, 2011, 38(2): 719-26. doi: 10.1118/1.3539749
[15] Appenzoller LM, Michalski JM, Thorstad WL, et al. Predicting dose-volume histograms for organs-at-risk in IMRT planning[J]. Med Phys, 2012, 39(12): 7446-61. doi: 10.1118/1.4761864
[16] Yang Y, Ford EC, Wu B, et al. An overlap-volume-histogram based method for rectal dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel injection[J]. Med Phys, 2013, 40(1): 011709. doi: 10.1118/1.4769424
[17] Moore KL, Brame RS, Low DA, et al. Experience-based quality control of clinical intensity-modulated radiotherapy planning[J]. Int J Radiat Oncol Biol Phys, 2011, 81(2): 545-51. doi: 10.1016/j.ijrobp.2010.11.030
下载:
计量
- 文章访问数: 1318
- HTML全文浏览量: 329
- PDF下载量: 540
